Among emerging antidiabetic agents, glucagon-like peptide-1 (GLP-1)-based therapies carry special cardiovascular implications, exerting both direct and indirect effects. The control of vascular permeability is of pivotal importance in vascular pathologies. The objective of the present study was to determine the effect of GLP-1 on endothelial barrier function and assess the underlying mechanism(s). Here we show for the first time that the stable GLP-1 analog exendin-4 attenuated the leakage of subcutaneous blood vessels in mice indexed by dye extravasation caused by injections of thrombin. Moreover, in cultured endothelial cells, exendin-4 significantly prevented the thrombin-induced FITCdextran permeability of endothelial monolayers via GLP-1 receptor. Immunofluorescence microscopy reveals that exendin-4 abrogates detrimental effects of thrombin on VE-cadherin and the F-actin cytoskeleton, with decreased stress fiber and gap formation. Importantly, exendin-4 reduced thrombin-induced tyrosine phosphorylation of VE-cadherin at Y731 and Y658. Moreover, small GTPase Rac1 was significantly activated as a result of exendin-4 treatment. The efficacy of exendin-4 to counteract the barrier-compromising effect of thrombin was blunted when Rac1 was inactivated by Rac1 inhibitor NSC-23766. Inhibition of PKA activity or small-interfering RNA for exchange protein directly activated by cAMP 1 (Epac1) decreased exendin-4-induced Rac1 activation and barrier enhancement, indicating the participation of both PKA and Epac1 in the barrier-stabilizing effect of exendin-4 elicited on thrombin-impaired barrier function. Thus, our findings have uncovered an unpredicted role for exendin-4 in the coordination of vascular permeability and clarified the molecular underpinnings that contribute to barrier restoration initiated by exendin-4.
THE ENDOTHELIUM LINING BLOOD vessels functions as a gatekeeper for movement of nutrients, solutes, liquid, and cells. Dysfunction of blood vessel integrity is implicated in several vascular pathologies, including inflammation, interstitial edema, sepsis, atherosclerosis, diabetes, tumor angiogenesis, and metastatic migration (9, 20, 25) . The specialized structures maintaining endothelial cell (EC)-to-cell adhesion include tight and adherens junctions (AJs) (20) . At endothelial AJs, VE-cadherin promotes homophilic adhesion and forms zipper-like structures along EC contacts (21, 47) . Exposure of ECs to several permeability mediators, such as thrombin, vascular endothelial growth factor, and histamine, results in tyrosine phosphorylation of VE-cadherin at Y731 and Y658 (22, 41, 42) , which may reduce the affinity for ␤-catenin and p120 binding, promoting its internalization (34, 41) .
Signaling via cAMP contributes to the regulation of barrier function (4) . The downstream pathways linking cAMP elevation to barrier-protective cytoskeletal rearrangements are numerous and involve cAMP effectors protein kinase A (PKA) and RAP1 guanidine exchange factor Epac1 (exchange protein directly activated by cAMP 1) (6, 11, 24) . Tightening of cell junctions depends on VE-cadherin clustering accompanied by recruitment of junction-associated actin filaments via the Rho GTPase Rac1 (10, 43) . Epac-mediated Rac1 activation results in increased junctional adhesions and reorganization of actin filaments (3, 4, 43) .
Glucagon-like peptide-1 (GLP-1) is an incretin hormone that gets secreted from intestinal L cells in response to nutritional stimuli, leading to pancreatic insulin secretion and suppression of glucagon release (15, 19) . The importance of the incretin system in glucose homeostasis is emphasized by the recent successful therapeutic exploitation of this system using GLP-1 receptor (GLP-1R) agonists and inhibitors of the dipetidyl peptidase 4 enzyme to overcome the extremely short half-life of native GLP-1 (14) . Previous researchers have demonstrated the presence of high-affinity receptors for GLP-1 in cardiomyocytes, endothelium, and vascular smooth muscle cells (39) . Emerging evidence suggests that GLP-1-modulating drugs may hold beneficial cardiovascular characteristics (36, 37) . A recent study showed that exendin-4, the stable GLP-1 analog, reduced retinal vascular leakage in diabetic Goto-Kakizaki rats by decreasing placental growth factor and intercellular adhesion molecule-1 expression (17) . Moreover, exendin-4 was found to suppress lipopolysaccharide (LPS)-mediated release of nuclear DNA-binding protein high-mobility group box 1 (HMGB1) and inhibited HMGB1-mediated hyperpermeability and leukocyte migration in septic mice (26) . Earlier study showed that GLP-1 attenuate LPS-induced microvascular permeability via GLP-1R/cAMP signaling pathways (13) . While these studies support a barrier-protective effect of GLP-1, the effect and molecular mechanisms of GLP-1 on thrombininduced endothelial permeability remain unknown. In this study, we investigated the hypothesis that exendin-4 protects against thrombin-induced endothelial barrier dysfunction through cAMP-mediated activation of Rac1. Herein, we show that exendin-4 is capable of improving thrombin-compromised EC barrier, and the barrier-protective effect can be achieved by the activation of PKA and Epac1/Rac1. Importantly, exendin-4 dramatically attenuates thrombin-induced tyrosine phosphorylation of VE-cadherin at Y731 and Y658. The analysis of the role of Rac1 demonstrates that Rac1 contributes to the barrier maintenance of exendin-4. These findings identify exendin-4 as a potential barrier-stabilizing agent for vascular leakage in hyperpermeability-associated disorders.
MATERIALS AND METHODS
Chemicals, reagents, and antibodies. Thrombin, exendin-4, exendin-(9 -39), forskolin, and Evans blue dye (EBD) were from Sigma (Sigma-Aldrich, St. Louis, MO). Antibodies against VE-cadherin and claudin-5 were from Santa Cruz Biotechnology (Santa Cruz, CA). The Rac1 Activation Assay Kit was from Millipore (Billerica, MA). Myristoylated PKA inhibitor amide [14] [15] [16] [17] [18] [19] [20] [21] [22] and Rac1 inhibitor NSC-23766 were from Calbiochem (La Jolla, CA). The cAMP Assay kit was from Enzo Life Sciences (Farmingdale, NY). The In Vitro Vascular Permeability Assay Kit was from BioVision (Mountain View, CA). The Nucl-Cyto-Mem Preparation Kit was from Applygen Technologies (Beijing, China). The PepTag Nonradioactive PKA Assay kit was from Promega (Madison, WI). Phospho-Tyr 731 VE-cadherin, phospho-Tyr 658 VE-cadherin, phospho-myosin light chain (MLC), and MLC antibodies were from Cell Signaling (Beverly, MA). Epac1-specific small-interfering RNAs (siRNAs) were purchased from Santa Cruz Biotechnology. Rhodamine/phalloidin was from Molecular Probes (Carlsbad, CA).
Isolation of human umbilical vein vascular EC. Human umbilical vein endothelial cells (HUVECs) were cultured as previously described (38) . The protocol was approved by the Peking University Institutional Human Sample Use Committee. Cells were maintained in M199 (GIBCO) supplemented with 20% fetal bovine serum (FBS), 20 mM HEPES (pH 7.4), 1 ng/ml of recombinant human fibroblast growth factor (Sigma-Aldrich), and 90 g/ml of heparin. In all experiments, HUVECs within five passages were used. At ϳ70% confluency, the cells were washed two times with serum-free medium and then maintained in M199 with 1% FBS for 12 h before use.
Transwell permeability assays. ECs were cultured with a density of 2 ϫ 10 6 cells/well on 24-well Transwell inserts (pore size 0.4 m; Corning, New York, NY). Medium was added to the bottom (500 l) and top (100 l) chamber. Quiescent ECs were treated with the agonists or drugs as indicated in the legends for Figs. 1-8. Thereafter, FITC-dextran (1 mg/ml, 40 kDa; Sigma-Aldrich) was given to the upper compartment together with or without 1 unit of thrombin for 30 min. At the end of treatment, 100 l of the medium were withdrawn from the lower compartment and transferred to 96-well black microplates. The fluorescence increase of the samples was detected with a SpectraFluorPlus plate reader (Tecan, Crailsheim, Germany) at excitation/emission wavelength of 492/520 nm. To evaluate FITC-dextran permeability, controls were set up for no treatment. Results are expressed as fold of control taken as one.
Measurement of cAMP level. Intracellular levels of cAMP were measured using a competitive ELISA, according to the manufacturer's instructions (Enzo Life Sciences). Briefly, quiescent ECs were incubated with 10 nM exendin-4 for indicated periods of time. Cells were lysed in 0.1 M HCl and 0.1% Triton X-100, and results were normalized to protein content. Absorbance is read at 405 nm.
Rac1 activity assay. GTP-bound active Rac1 assay was performed using a Rac1 Activation Assay Kit (Millipore), according to the manufacturer's instructions. Briefly, Quiescent ECs were stimulated with 10 nM exendin-4 for indicated periods of time and lysed at 4°C in a pull-down lysis buffer. p21-Activated kinase-conjugated protein beads were incubated with the cell lysates at 4°C for 1 h. Eluted proteins were subjected to SDS-PAGE, followed by immunoblotting with anti-Rac1 antibody. The levels of activated Rac1 were normalized to total Rac1 levels.
Immunofluorescence staining. Confluent ECs grown on cover slips were fixed with 4% paraformaldehyde for 15 min, permeabilized in 0.2% Triton X-100 for 10 min, and blocked for 1 h with 1% BSA and 0.1% Triton X-100 in PBS. Cover slips were incubated at 4°C overnight with anti-VE-cadherin antibody (at 1:200 dilution) in PBS with 0.1% BSA. Thereafter, the cells were incubated for 1 h at room temperature (RT) with FITC-conjugated rabbit anti-goat IgG. For visualization of F-actin, EC monolayers were stained with rhodamine phalloidin for 30 min at RT. Nuclei were labeled with DAPI (Roche Diagnostics, Indianapolis, IN) for 10 min. Images were captured using Leica TCS SP2 laser scanning confocal microscopy (Leica Microsystems, Wetzlar, Germany).
The area of intercellular gaps was quantified using Image J software (National Institutes of Health) by manually outlining cells and selecting for gaps. Images were taken of cells stained for VE-cadherin at ϫ40 magnification (20 -25 cells/microscope field). The cell periphery, outlined by VE-cadherin staining, was traced by using the freehand selection tool. Next, the ImageJ analyze particles function was used to measure areas within the freehand selection. The areas for each selection were summed, and then the unoccupied area was calculated and divided by the total surface area. Gap areas were quantified in three different randomly chosen microscopic fields for each condition per experiment. For each group, seven experiments were performed. The values of gap area are calculated as a percentage of the total surface area and normalized to that of the control group. An observer blinded to the experimental conditions was asked to analyze the differences in interendothelial gaps.
Stress fiber density was quantified using ImageJ software, as described previously (35) . Briefly, the TIFF images were converted to eight-bit grayscale, and the threshold tool was used to determine an optical density limit that encapsulated most F-actin bundles, eliminating background fluorescence. One observer blinded to the experimental conditions drew a line perpendicular to the longitudinal axis through each cell center and at points of membrane tethering. The plot profile function was then used to generate average pixel intensities at several intervals along the line of interest. The density was calculated by measuring the area under the curve of pixel intensity above the threshold limit divided by the total area. A graphic depiction was then generated where the x-axis represented distance across the cell, and the y-axis represented levels of fluorescence. On average, 8 -10 cells were analyzed per condition.
Preparation of membrane extracts. Membrane proteins were extracted by using the Nucl-Cyto-Mem Preparation Kit according to the manufacturer's protocol (Applygen Technologies). Briefly, ECs treated with thrombin in the presence or absence of exendin-4 (10 nM) were harvested and resuspended in 500 l of cytosol extraction reagent and homogenized with 20 passes in a 2-ml dounce homogenizer. The homogenate was centrifuged at 1,000 g for 5 min at 4°C to pellet nuclei and cellular debris. The resulting postnuclear supernatants were then mixed with 50 l of membrane extraction reagent for 5 min at 4°C and subjected to centrifugation at 16,000 g for 45 min at 4°C. The resulting pellet and supernatant fractions were designated membrane and cytosol, respectively.
Western blotting. Proteins were extracted from the cells as described previously (38) . Equal amounts of protein homogenate were resolved on 4 -12% SDS-PAGE and transferred to polyvinylidene difluoride membranes. Blots were blocked in TBS-Tween 20 buffer containing 5% nonfat milk and probed with primary antibodies overnight at 4°C. Blots were then incubated with horseradish peroxidase-conjugated secondary antibodies at RT for 1 h. Blots were analyzed with an enhanced chemiluminescence detection system and detected by using the ChemiDoc XRS system (Bio-Rad).
PKA activity assay. PKA activity measurement was performed using a PepTag Nonradioactive PKA Assay kit (Promega) according to the manufacturer's protocol. ECs were stimulated with each reagent and lysed. PepTag A1 peptide was added to the lysates. Phosphorylated peptide was isolated by 0.8% agarose gel electrophoresis. Bands were visualized using an ultraviolet transilluminator.
Epac1 gene silencing via siRNA. Human Epac1 siRNA were delivered into 60 -70% confluent cells using siPort NeoFx reagent (Ambion), following the manufacturer's instructions. Briefly, quiescent ECs were incubated with 20 nM of Epac1 siRNA (or scrambled siRNA) for 6 h in serum-free media. Next, medium with 20% serum was added for 42 h. RNAi-mediated effect on FITC-dextran passage was assessed 48 h posttransfection. Transfected ECs were seeded in 24-well Transwell inserts and treated with various drugs. Nonspecific, scrambled siRNAs were used as a control.
In vivo subcutaneous vascular leakiness assay. Three-week-old male BALB/c white mice were housed on a 12:12-h light-dark cycle with ad libitum access to food and water. All animal procedures were approved by the Institutional Animal Care and Use Committee of Peking University. To determine the dose effect on thrombin-induced barrier dysfunction, various concentrations of exendin-4 or vehicle control were injected subcutaneously two times daily (at 8:00 A.M. and 7:00 P.M.) for 1 day. The animals were randomly divided into the following five groups (n ϭ 7 each group): group 1, control group that received no treatment; group 2 Ϫ1 ·day Ϫ1 (high dose) was subcutaneously injected at different time points (n ϭ 5 mice each time point) for 1 day. The dose was determined with reference to a previously reported study (1) . One day after injection, 100 l of 2% EBD (Sigma-Aldrich) in sterile PBS were injected in the tail vein. Injection sites were randomly chosen to avoid bias. Thirty minutes thereafter, mice received subcutaneous administration of 100 l of either thrombin (2 U) or saline control. Thrombin was carefully injected in subcutaneous pockets on the back of mice. For each mouse, thrombin was injected in one site on the right side of the mouse dorsum, and saline was to the left side. The mice were killed after 30 min, and thereafter the skin was excised and weighed. To quantify the vascular permeability, the extravasated dye was eluted from the dissected skin with formamide at 56°C, and optical density was quantified by measuring absorbance at 624 nm with a microplate reader (Tecan). The absorbance measured was normalized to the weight of the skin excised.
Statistical analysis. Quantitative data are expressed as means Ϯ SE. Differences were analyzed via one-way ANOVA followed by a Newman-Keuls test (multigroup comparisons). A P value of Ͻ0.05 was considered statistically significant. Nonquantitative results were representative of at least three independent experiments.
RESULTS

Exendin-4 promotes endothelial barrier function both in vitro and in vivo.
We examined exendin-4-mediated endothelial barrier enhancement in vivo in a mouse model. As shown in Fig. 1A , EBD extravasation was more pronounced in the thrombin group (Fig. 1A) . However, a single preadministration of high-dose exendin-4 (24 nmol·kg Ϫ1 ·day Ϫ1 ) time-dependently suppressed thrombin-induced EBD extravasation (Fig.  1A, top) . Quantification of EBD extravasation showed less endothelial leakage in combination of thrombin and exendin-4 compared with the thrombin treated alone (Fig. 1A, bottom) . In addition, the dose-dependent barrier enhancement response of exendin-4 was also examined in vivo (Fig. 1B) . Exendin-4 pretreatment at 0.24, 2.4, and 24 nmol·kg Ϫ1 ·day Ϫ1 dose-dependently reduced the thrombin-induced increase in EBD extravasation by 7.6, 58.1, and 70.5%, respectively (Fig. 1B) .
Next, we measured EC monolayer permeability to FITCdextran in vitro. As presented in Fig. 1C , treatment with thrombin resulted in a significant increase in FITC-dextran passage across the EC monolayer. Preincubation of ECs with exendin-4 dose-dependently prevented the thrombin-induced increase in permeability to FITC-dextran, with a maximum response to 10 nM exendin-4 (Fig. 1C) . In addition, a maximal barrier-protective response was observed by 1 h of exendin-4 stimulation (Fig. 1D) . Moreover, pretreatment with the GLP-1R antagonist exendin-4-(9 -39) significantly reversed the attenuating effect of exendin-4 on FITC-dextran passage (Fig. 1E) .
cAMP/PKA signaling is required for exendin-4-mediated endothelial barrier enhancement. Because activation of GLP1Rs may lead to the G s -mediated pathway, including direct stimulation of adenylate cyclase, elevation of cAMP levels, and cAMP-dependent activation of PKA (13), we investigated the involvement of this signaling cascade in the exendin-4 barrier-protective effect. Treatment of ECs with 10 nM exendin-4 markedly increased intracellular cAMP levels ( Fig. 2A) . The analysis of PKA activity showed that exendin-4 significantly increased PKA activity up to 2.1-fold over the control. This increase was reduced by pretreatment with the cellpermeable PKA inhibitor PKI14-22 (Fig. 2B) . To further confirm PKA participation in exendin-4-mediated barrier stabilization, we used PKI14-22 (28) in FITC-dextran Transwell experiments. As shown in Fig. 2C , PKI14-22 significantly attenuated exendin-4-induced barrier enhancement. Therefore, activation of cAMP/PKA signaling is crucial for the barrierstabilizing effect of exendin-4 in ECs.
Exendin-4 promotes cytoskeletal rearrangement and AJ assembly. Next, the effects of exendin-4 on AJ assembly and actin rearrangement in ECs were examined. As shown in Fig. 3A , VE-cadherin was located at cell-cell contact areas under resting conditions. Thrombin treatment caused a partial loss of VEcadherin signal at the cell border concomitant with the transition of the border staining pattern from a straight to a zigzag line (Fig. 3A, top) . Small gaps at cell-to-cell junctions could be observed in thrombin-treated cells as described (7, 29, 46) (Fig.  3A, top) . In contrast, gaps were barely visible in exendin-4-pretreated monolayers (Fig. 3A, top) . Pretreatment with exendin-4 resulted in a reorganization of VE-cadherin at the plasma membrane that appeared as a linearized adherence junction band compared with control cells (Fig. 3A, top) . Quantification of the interendothelial gap area of the monolayer showed that thrombin induced a seven-to eightfold increase in gap area (Fig. 3B) . Exendin-4 significantly reduced the thrombin-induced increase in gap formation (Fig. 3B) .
Immunofluorescence analysis of phalloidin-labeled cells revealed that thrombin-treated ECs had considerably more stress fibers traversing the cytoplasm than control cells, and more intercellular gaps (Fig. 3A, bottom) . Stress fibers within thrombin-treated ECs were organized and uniform throughout each cell, whereas exendin-4-pretreated ECs were characterized by the accumulation of cortical actin (Fig. 3A, bottom right) . Also, this cortical F-actin network is less pronounced in exendin-4 alone-treated cells (Fig. 3A, bottom) .
Stress fibers were then quantified by using ImageJ software as described in MATERIALS AND METHODS. We quantified stress fiber density by incorporating a line profile across the cytoplasm that identified stress fibers by their increased fluorescence relative to areas devoid of stress fibers (Fig. 4A, left) . Sharp distinct peaks in fluorescence intensity within each line profile represented individual stress fibers crossed by the lines (Fig. 4A, right) . Quantification of these peaks in three different regions per cell, in 8 -10 cells/group, revealed a three-to fourfold increase in stress fibers in thrombin-stimulated ECs compared with levels in control cells (Fig. 4B) , whereas exendin-4 significantly reduced the thrombin-provoked increase in stress fiber formation (Fig. 4B) . Stress fiber density in exendin-4 alone-treated cells remained unaffected (Fig. 4B) .
Phosphorylation of regulatory MLC is a key mechanism of EC contraction and thrombin-induced barrier dysfunction (16) . We then tested whether exendin-4 suppresses thrombin-induced MLC phosphorylation in ECs. Exposure of ECs to thrombin led to the phosphorylation of MLC on Thr 18 /Ser 19 ( Fig. 4C) . However, exendin-4 pretreatment blocked thrombininduced MLC phosphorylation (Fig. 4C) . Exendin-4 alone had no significant effect on MLC phosphorylation (Thr 18 /Ser 19 ) in ECs compared with control (Fig. 4C) . These results suggest Fig. 3 . Exendin-4 induces cytoskeletal rearrangement and adherens junctions assembly. A: quiescent EC monolayers were pretreated with 10 nM exendin-4 for 1 h before stimulation with thrombin (1 U) for 30 min and then immunostained for VE-cadherin (green, top) and F-actin (red, bottom). Cells were stained with rhodamine phalloidin to demonstrate cytoskeletal actin. Nuclei were visualized with DAPI (blue). Arrows indicate interendothelial gaps. Scale bar, 50 m; n ϭ 7. B: quantification of interendothelial gap area was shown in the corresponding panels in A. The values of gap area are calculated as a percentage of the total surface area and normalized to that of the control group; n ϭ 7. *P Ͻ 0.05 vs. control. #P Ͻ 0.05 vs. thrombin. that the suppression of MLC phosphorylation could be one of the plausible mechanisms by which exendin-4 alleviates barrier compromise in ECs exposed to thrombin.
Exendin-4 prevents tyrosine phosphorylation of VE-cadherin at Y731 and Y658.
It is possible that the promising effect of exendin-4 on EC barrier function is mediated by altered expression of adhesion and tight junction-associated proteins. Of particular interest, exendin-4 had no effect on the total expression of either VE-cadherin or claudin-5 (Fig. 5A) . Because thrombin activates phosphorylation of VE-cadherin at its Y731 and Y658 residues (22, 42) , it was of interest to investigate if exendin-4 affects tyrosine phosphorylation of VEcadherin. To test this, the effect of exendin-4 on the expression of phospho-VE-cadherin proteins was examined. Results shown in Fig. 5 , B and C, demonstrated that thrombin resulted in dramatic phosphorylation of VE-cadherin at Y731 and Y658. However, the increases in phosphorylation of Y731 and Y658 were significantly reduced by exendin-4 (Fig. 5, B and C) . VE-cadherin phosphorylation may promote its internalization, which has been reported to be a crucial step in the increase of vascular permeability (34, 41) . It was of great interest to examine if exendin-4 affects the distribution of VE-cadherin.
As shown in Fig. 5D , upon endothelial cytosol/membrane fractionation, thrombin treatment reduced membrane surface VE-cadherin and increased VE-cadherin internalization. Importantly, exendin-4 strongly inhibited thrombin-induced internalization of VE-cadherin from the cell membrane (Fig. 5D) . Furthermore, pretreatment of ECs with the GLP-1R antagonist exendin-(9 -39) abrogated exendin-4 suppression of VE-cadherin phosphorylation at Y731 and Y658 (Fig. 5, E and F) .
Exendin-4 counteracts the barrier-compromise effect of thrombin through the Epac1/Rac1 signaling pathway. To elucidate whether or not Epac1 is also critical for exendin-4-mediated barrier enhancement, we depleted Epac1 in ECs with the siRNA specific for Epac1. As shown in Fig. 6A , Epac1 depletion reduced exendin-4-mediated barrier stabilization, implying the involvement of Epac1 in the exendin-4-induced barrier-protective effect. Immunoblot analysis confirmed the downregulation of Epac1 expression (Fig. 6A, right) . Rac1, a member of the Rho family GTPases, enhances endothelial barrier through actin cytoskeleton rearrangement (4). We hypothesize that Rac1 contributes to exendin-4-induced barrier maintenance as a downstream target of the Epac1 pathway. As shown in Fig. 6B , exendin-4 time-dependently increased the Fig. 6C) . In addition, preincubation with the PKA inhibitor PKI14-22 significantly concealed the increasing effect of exendin-4 on Rac1 activity (Fig. 6D) . As depicted in In the next experiments we explored the role of Rac1 in exendin-4-induced actin cytoskeletal remodeling. Treatment with exendin-4 enhanced VE-cadherin signaling at the cell Quiescent ECs were stimulated with 10 nM exendin-4 for indicated periods of time. Cell lysates were subjected to Western blot analysis. Protein bands were quantified densitometrically as the ratio of VE-cadherin/␤-actin and claudin-5/␤-actin; n ϭ 3. B and C: effect of exendin-4 on tyrosine phosphorylation of VE-cadherin at Y731 and Y658. Quiescent ECs were incubated with 10 nM exendin-4 for 1 h before stimulation with thrombin for 30 min. Cell lysates were subjected to Western blot analysis using specific antibodies against phospho-Tyr 731 -VE-cadherin (B) and phospho-Tyr 658 -VE-cadherin (C). Protein bands were quantified densitometrically as the ratio of phospho-Tyr 731 -VE-cad/␤-actin and phospho-Tyr 658 -VE-cad/␤-actin; n ϭ 3. *P Ͻ 0.05 vs. control. #P Ͻ 0.05 vs. thrombin. D: exendin-4 inhibits thrombin-induced internalization of VE-cadherin from the cell membrane. Quiescent ECs were pretreated with 10 nM exendin-4 for 1 h before stimulation with thrombin for 30 min. Membrane and cytosol proteins were prepared as described in MATERIALS AND METHODS. Fractions were analyzed for VE-cadherin content using anti-VE-cadherin antibody. E and F: exendin-4 inhibits the phosphorylation of VE-cadherin at Y731 and Y658 via GLP-1 receptor. Quiescent ECs were pretreated with 100 nM GLP-1 antagonist exendin-(9 -39) for 30 min before incubation with 10 nM exendin-4 for 1 h, followed by thrombin treatment for 30 min. Protein expression of phospho-Tyr 731 -VE-cad (E) and phospho-Tyr 658 -VE-cad (F) was analyzed as in B and C, respectively; n ϭ 3. *P Ͻ 0.05 vs. control.
border, reduced the number of actin stress fibers, and induced the formation of a cortical actin rim (Fig. 7A) . However, inhibition of Rac1 activity increased the assembly of stress fibers and caused a partial loss of VE-cadherin signal at the cell border concomitant with the transition of the border-staining pattern from a straight to a zigzag line (Fig. 7A) . As shown in Fig. 7A , paracellular gaps appeared in NSC-23766-pretreated ECs exposed to exendin-4.
We quantified stress fiber density by incorporating a line profile across the cytoplasm that identified stress fibers by their increased fluorescence relative to areas devoid of stress fibers (Fig. 7B) . Quantification of fluorescent peaks in three different regions per cell, in 8 cells/condition, showed an almost threefold increase in stress fiber density in NSC-23766-pretreated ECs exposed to exendin-4 compared with levels in untreated cells, whereas stress fiber density was not altered in exendin-4-treated cells (Fig. 7C) .
In addition, exendin-4 ability to counteract thrombinincreased FITC-dextran passage through the EC monolayers was attenuated by NSC-23766 (Fig. 7D) . These results suggest a critical role of the Rac1-dependent pathway in EC cytoskeletal remodeling and barrier maintenance exhibited by exendin-4.
DISCUSSION
Growing evidence suggests GLP-1-modulating drugs to hold beneficial cardiovascular characteristics in the heart (31, 32, 48) and vasculature (2, 12, 18, 23, 37, 44, 49) . Here we report that the GLP-1 analog exendin-4 protects against thrombin-induced endothelial barrier dysfunction both in vitro and in vivo. In addition, our results show that exendin-4 induces rearrangement of the VE-cadherin and actin cytoskeleton in response to thrombin. Mechanistically, exendin-4 inhibits the tyrosine phosphorylation of VE-cadherin at both Y731and Y658 and activates the barrier-stabilizing cAMP/PKA pathway, as well as the cAMP/Epac1/Rac1 pathway. In addition, exendin-4 also suppresses thrombin-induced phosphorylation of MLC on Thr 18 /Ser 19 in ECs. EC control the passage of plasma constituents and circulating cells from blood to the underlying tissues. This specialized function is lost or impaired in many severe disorders, such as inflammation, sepsis, atherosclerosis, diabetes, or heart failure, which leads to severe, and sometimes fatal, organ dysfunction (7, 9) . GLP-1 is an incretin hormone capable of cytoprotective actions in addition to its glucose-lowering effect. Recent studies have begun to uncover the mechanisms through which GLP-1 exerts protective effects in the cardiovascular system. GLP-1 protects the cardiac microvessels against oxidative stress and apoptosis in diabetes via a cAMP/PKA/Rho-dependent mechanism (48). GLP-1 prevents H 2 O 2 -induced EC senescence through the activation of PKA (33) . The GLP-1 analog liraglutide reduces monocyte vascular adhesion and prevents cardiac dysfunction of a mouse model of obesity (32) . Liraglutide suppresses macrophage foam cell formation and atherosclerosis (44) . However, the molecular action of GLP-1 on thrombin-induced EC barrier dysfunction is unknown. In the present study, we delineated the effect of exendin-4, the stable GLP-1 analog, on thrombin-impaired barrier function and analyzed the downstream pathways linking exendin-4 treatment to the barrier enhancement. Experiments were performed by using FITC-dextran transfer of EC monolayers in vitro and subcutaneous vascular leakage assay in vivo. Our results demonstrated that exendin-4 markedly attenuated thrombin-induced permeability for FITC-labeled dextran. In addition, in vivo experiments revealed that exendin-4 reduced the leakage of subcutaneous blood vessels in mice indexed by EBD extravasation caused by thrombin injections.
Immunofluorescence analysis of cytoskeletal remodeling revealed that barrier-protective effects of exendin-4 were accompanied by dramatic reduction of thrombin-induced stress fiber and paracellular gap formation. Focusing on paracellular permeability, barrier destabilization is described as the formation of minute interendothelial gaps (7, 8) . These gaps are mainly regulated by subcellular systems that form adhesive cell-cell contacts (e.g., AJ/VE-cadherin) and exhibit retraction forces (e.g., the contractile apparatus/actomyosin). Previous studies show that thrombin-induced EC permeability is mediated through MLC phosphorylation and cell contraction, thereby leading to increased vascular permeability (16) . The level of phospho-MLC could be modulated by the activity of PKA, known to decrease the MLC phosphorylation level (27) . In the present study, exendin-4 suppressed thrombin-induced phosphorylation of MLC, providing further evidence showing the protective action of exendin-4 against endothelial barrier dysfunction. Therefore, the role of MLC dephosphorylation in the enhancement of barrier function in response to exendin-4 should not be overlooked.
Direct tyrosine phosphorylation of Y731 and Y658 sites induced by thrombin disrupts the VE-cadherin interaction with ␤-catenin and p120, respectively, consequentially promoting actin remodeling followed by the deformation of cell shape, resulting in gaps between cells (8, 42) . To further elucidate the pathway through which exendin-4 attenuated thrombin-impaired barrier function, we test the tyrosine phosphorylation of VE-cadherin. Here we showed that thrombin inductions of VE-cadherin phosphorylation at Y731 and Y658 were significantly inhibited by exendin-4, although the underlying mechanism has not yet been fully clarified. In the vasculature, the regulation of VE-cadherin endocytosis is critical for controlling endothelial permeability and barrier function (7) . In line with this concept, we report here that thrombin apparently increased VE-cadherin internalization. Our results are in accordance with the studies of Bubik et al. (6) , who have shown that treatment with thrombin for 30 min induced a rapid VE-cadherin internalization. Importantly, exendin-4 abolished thrombin-induced internalization of VE-cadherin in our study. Orsenigo et al. (34) report that bradykinin leads to VE-cadherin ubiquitination and that this process requires phosphorylation of Y658 and Y685. In this study, we hypothesize that dephosphorylation of Y731 and Y658 in VE-cadherin by exendin-4 desensitizes VE-cadherin to the action of thrombin, which inhibits rapid VE-cadherin internalization and ubiquitination. Further work is required to define this mechanism in detail.
GLP-1R is categorized as a G s protein-coupled receptor, which is a well-known direct activator of adenylate cyclase.
The two main signaling axes downstream of cAMP are activation of PKA as well as engagement of Epac and its effector GTPase Rac1 (11) . Our novel data show that both Epac1 and PKA pathways mediate exendin-4-induced Rac1 activation and the EC barrier-protective response. Although some cellular responses to elevation of intracellular cAMP are regulated exclusively by PKA or Epac1 signaling pathways, or PKA and Epac1 may even play opposing roles (30) , in many processes Epac1 and PKA pathways are frequently interconnected (11) . Our studies showing that exendin-4-mediated barrier enhancement in ECs was attenuated by the inhibition of PKA support the implication of the cAMP/PKA pathway in the barrier-stabilizing effect of exendin-4. To ascertain that the elevation of the Epac1/Rac1 signaling pathway by exendin-4 is also causative to the exendin-4 improvement of the barrier function, we tested the effect of Epac1 depletion on exendin-4 alleviation of thrombin-induced barrier disruption. As expected, silencing of Epac1 abrogated exendin-4-induced barrier protection. These findings support the concept that both the cAMP/PKA pathway and cAMP/Epac1/ Rac1 pathway contribute to the endothelial barrierstabilizing effect of exendin-4.
It is well established that activation of Rho GTPase Rac1 reorganizes the actin cytoskeleton at the cell periphery and thus strengthens the AJ (3, 4, 11, 43) . However, there are no published data on the implication of Rac1 in exendin-4-mediated endothelial barrier stabilization. Here, we reported that exendin-4 significantly increased the activity of Rac1. Our results showing that pharmacological inhibition of Rac1 with the specific inhibitor NSC-23766 attenuated the protective effect of exendin-4 elicited on thrombin-impaired EC monolayers suggest the implication of Rac1 in exendin-4-mediated barrier protection. Notably, the underlying mechanism by which exendin-4 increases the activation of Rac1 appears to involve PKA as well as the Epac1 pathway because the PKA inhibitor PKI14-22 or Epac1 deletion reversed the increasing effect of exendin-4 on Rac1 activation. In this regard, the Fig. 8 . Schematic representation of putative EC barrier-protective molecular mechanisms activated by exendin-4. Stimulation of EC with exendin-4 elevates intracellular cAMP levels and stimulates cAMP-dependent PKA and cAMP-activated guanine nucleotide exchange factor Epac1. Activated PKA and Epac1 promote Rac1 activation. Activated Rac1 promotes actin cytoskeletal remodeling by reducing stress fiber formation and stabilizing cortical actin. Activation of Epac1 strengthens the endothelial barrier by stabilizing adhesion junctions (VE-cadherin internalization, Tyr 731 and Tyr 658 phosphorylation). In addition, exendin-4-mediated activation of PKA may cause cytoskeletal remodeling by Rac1-independent mechanisms, for example, via modulation of myosin light chain phosphorylation. AJ, adherens junctions. enhancement of Rac1 activation by both PKA-and Epac1-mediated signaling pathways has been shown by several investigators (4, 5, 11, 24, 40, 45) . Thus, Rac1 may serve as a convergence point between PKA and Epac1 signaling mediating exendin-4-induced barrier protection.
In conclusion, our results summarized in Fig. 8 suggest that exendin-4 ameliorates thrombin-induced barrier dysfunction both in vitro and in vivo. The enhancement of barrier function induced by exendin-4 may be attributed to its ability to promote actin cytoskeletal rearrangement and AJ assembly. Mechanistically, exendin-4 attenuates the tyrosine phosphorylation of Y731 and Y658 in VE-cadherin. Both PKA and Epac1 signaling cascades mediate exendin-4-induced Rac1 activation and EC cytoskeletal remodeling, leading to enhancement of EC monolayer barrier properties. In addition, exendin-4 suppresses thrombin-induced MLC phosphorylation. Given that EC hyperpermeability and dysfunction play a critical role in the pathogenesis of various vascular diseases in diabetes and that exendin-4 exerts this barrier-protective effect on ECs, our findings may provide a novel cellular mechanism that may underlie some of the reported beneficial effects of exendin-4 in modulation of vascular function.
